A little glimpse towards ibrutinib

Description

The new anti-cancer drug ibrutinib (Imbruvica), developed by the J & J pharmaceutical company is significantly more effective than standard chemotherapy for leukemia.

During the trial, some patients with chronic lymphocytic leukemia received ibrutinib, and some patients received chemotherapy. It turned out that in the first group the survival rates were 90%, in the chemotherapy group - 81%. The researchers note that in the group of participants receiving ibrutinib, remission rates were in four out of ten patients, in the chemotherapy group - four out of a hundred.

It should also be noted that patients responded more quickly to ibrutinib than to chemotherapy. Another advantage of the new drug over chemotherapy is the fewer side effects associated with its use.

Scientists believe that ibrutinib can replace standard chemotherapy. It is especially indicated for patients who have developed resistance to chemotherapy. When we talk about Ibrutinib price in USA then it comes to most expensive cancer medicine.

Indications for use

Ibrutinib should be taken once a day with a glass of water at approximately the same time every day. Ibrutinib capsules must be swallowed whole with water; Do not open, break or chew capsules. Imbruvica should not be taken with grapefruit juice.

Treatment of adult patients with chronic lymphocytic leukemia who have received at least one line of therapy, or patients with a 17p deletion or TP53 mutation who have contraindications to chemo immune therapy, as first-line therapy.

Use during pregnancy and breastfeeding

Contraindicated for use during pregnancy and breastfeeding.

Use for liver dysfunction

Contraindication: severe renal impairment; severe liver dysfunction (class C on the Child-Pugh scale).

Use for renal impairment

In patients with mild or moderate renal impairment (creatinine clearance more than 30 ml/min), no dose adjustment is required. There are currently no data available in patients with severe renal impairment or on dialysis.

Contraindication: severe renal impairment, patients on dialysis.

Use in elderly patients

The need for dose adjustment depending on age has not been confirmed.

Side effects

Data on side effects of ibrutinib are based on data obtained during clinical trials and during the post-marketing period.

The most commonly observed adverse reactions were: diarrhea, neutropenia, bleeding (eg, bruising), musculoskeletal pain, vomiting, rash and fever. The most commonly observed grade III and IV adverse reactions were: neutropenia, pneumonia, thrombocytopenia and febrile neutropenia.

Adverse reactions associated with ibrutinib therapy in patients with B-cell malignancies and adverse reactions observed during the post-marketing period are summarized in Table 2 and are listed according to organ system classification and frequency distribution.

Storage

Store at a temperature not exceeding 25 °C in a place protected from light. Keep out of the reach of children.

Precautions

• Caution should be used when using Ibrutinib in patients with a history of heart disease, infection, or bleeding disorders.

• Routine blood tests are needed to track counts of different types of blood cells and indications of complications.

• The patient should tell the healthcare provider about all other medications being used, since Ibrutinib can affect many medications.

• Stay away from grapefruits and Seville oranges during treatment, as they may interfere with Ibrutinib in the blood.

Patients should notify their healthcare provider immediately of any unusual symptoms or side effects. Regular medical follow-ups are important to monitor the effectiveness of use and monitor adverse reactions.

Conclusion

In India, generic Ibrutinib is available in many supply channels such as hospitals, local pharmacies and online drug stores for patients. Such wide availability means that more patients can benefit from this advanced generic treatment, making it very productive in the treatment of diseases as serious as cancer, for example chronic lymphocytic leukemia and mantle cell lymphoma.